OXFORD, England — ¹û¶³ÊÓƵ, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, has today announced the appointment of Dr. Laura Trespidi as Chief Development Officer.
Dr. Trespidi brings more than 30 years’ of experience in global pharmaceutical and biotechnology companies, across clinical product development and manufacturing, from pre-clinical research through to market approvals and global product launches. Most recently as Senior Vice President, Chemistry, Manufacturing and Controls (CMC), Supply Chain and Technical Operations at Summit Therapeutics, Dr. Trespidi has successfully led global CMC and External Manufacturing teams through the development and market preparedness of investigational medicines, including end-to-end supply chain and manufacturing readiness and expansion.
Dr. Trespidi’s expertise extends further to formulation development, technology transfers, outsourcing and offshoring, with additional experience developing and executing change management strategies. Throughout her career, Dr. Trespidi has played a pivotal role in over 40 first-in-human clinical trials and pre-clinical trials, as well as contributing to four New Drug Applications (NDA) and market approvals, and over 40 Investigational New Drug (IND) applications.
The world-class leadership and technical expertise gained at Summit Therapeutics and other leading companies such as Mundipharma, Shire Pharmaceuticals and Gl
